Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy - Report - MDSpire
Advertisement
Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy
Clinical Report: Increased Levels of Serum Plasminogen Activator Inhibitor-1 in Epilepsy
Overview
This study found that serum levels of Plasminogen Activator Inhibitor-1 (PAI-1) are significantly elevated in pediatric epilepsy patients and correlate with seizure frequency, drug resistance, and neuroinflammatory markers.
Background
Epilepsy is a prevalent neurological disorder in children, with a significant portion of patients experiencing drug-resistant epilepsy. Understanding the underlying mechanisms, including neuroinflammation and blood-brain barrier disruption, is crucial for identifying new therapeutic targets and biomarkers. PAI-1's role in these processes has not been thoroughly investigated in pediatric epilepsy.
Data Highlights
Parameter
Epilepsy Patients
Healthy Controls
p-value
PAI-1 Levels (ng/mL)
28.47 ± 12.10
11.35 ± 5.05
< 0.001
Key Findings
Serum PAI-1 levels are significantly higher in epilepsy patients compared to healthy controls.
PAI-1 levels correlate positively with seizure frequency (r = 0.537, p < 0.001).
Patients with drug-resistant epilepsy have significantly elevated PAI-1 levels (p < 0.001).
PAI-1 is an excellent diagnostic biomarker for epilepsy (AUC = 0.916).
Higher PAI-1 levels correlate with neuroinflammatory markers (IL-6: r = 0.270, p < 0.001).
PAI-1 levels are associated with poorer quality of life scores (r = −0.227, p < 0.001).
Clinical Implications
Elevated PAI-1 levels may indicate a higher disease burden and potential treatment resistance in pediatric epilepsy patients.
Conclusion
PAI-1 is a significant biomarker in pediatric epilepsy, correlating with seizure burden and neuroinflammatory processes.
